Analysts Set Compugen Ltd. (NASDAQ:CGEN) PT at $5.33

Compugen Ltd. (NASDAQ:CGENGet Free Report) has earned a consensus rating of “Moderate Buy” from the five ratings firms that are currently covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation and four have assigned a buy recommendation to the company. The average twelve-month price objective among brokerages that have issued a report on the stock in the last year is $5.33.

Several research analysts have recently weighed in on CGEN shares. Stifel Nicolaus lifted their target price on shares of Compugen from $3.00 to $4.00 and gave the stock a “buy” rating in a research report on Tuesday, December 19th. StockNews.com downgraded shares of Compugen from a “hold” rating to a “sell” rating in a research report on Thursday.

Read Our Latest Analysis on CGEN

Institutional Trading of Compugen

Several large investors have recently modified their holdings of CGEN. Mariner LLC boosted its holdings in shares of Compugen by 207.3% during the 4th quarter. Mariner LLC now owns 36,831 shares of the biotechnology company’s stock worth $26,000 after buying an additional 24,844 shares during the period. Virtu Financial LLC bought a new stake in Compugen in the 1st quarter valued at $37,000. Envestnet Asset Management Inc. boosted its holdings in Compugen by 68.1% in the 2nd quarter. Envestnet Asset Management Inc. now owns 35,536 shares of the biotechnology company’s stock valued at $40,000 after purchasing an additional 14,393 shares during the period. Geode Capital Management LLC boosted its holdings in Compugen by 49.4% in the 2nd quarter. Geode Capital Management LLC now owns 40,579 shares of the biotechnology company’s stock valued at $46,000 after purchasing an additional 13,409 shares during the period. Finally, Susquehanna International Group Ltd. bought a new stake in Compugen in the 1st quarter valued at $56,000. 13.25% of the stock is owned by institutional investors.

Compugen Price Performance

Shares of CGEN opened at $2.42 on Tuesday. The firm’s 50 day moving average is $1.53 and its 200-day moving average is $1.15. The stock has a market capitalization of $209.62 million, a P/E ratio of -6.54 and a beta of 2.80. Compugen has a 12-month low of $0.53 and a 12-month high of $2.69.

Compugen (NASDAQ:CGENGet Free Report) last released its earnings results on Tuesday, November 7th. The biotechnology company reported ($0.11) earnings per share for the quarter, missing the consensus estimate of ($0.09) by ($0.02). As a group, equities research analysts forecast that Compugen will post -0.34 EPS for the current fiscal year.

Compugen Company Profile

(Get Free Report

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer.

Featured Stories

Analyst Recommendations for Compugen (NASDAQ:CGEN)

Receive News & Ratings for Compugen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Compugen and related companies with MarketBeat.com's FREE daily email newsletter.